Table 1.

Body weight changes, body weight relative to controls and incidence of non-neoplastic lesions at the site of application in F344/N rats and B6C3F1/N mice treated dermally for 3 months with pyrogallol.

			Number of Animals with Lesion (severity)
Dose (mg/kg)	Mean change in body weight (g)	Final weight relative to controls (%)	Squamous hyperplasia	Hyperkeratosis	Chronic active inflammation	Ulcer
Male F344/N rats
0	224 ± 5		1 (1.0)	0	0	0
9.5	225 ± 9	100	10** (1.0)	10** (1.1)	9** (1.1)	0
18.75	231 ± 6	102	10** (1.0)	10** (1.3)	9** (1.2)	0
37.5	226 ± 6	101	10** (1.0)	10** (1.7)	10** (1.0)	0
75	215 ± 6	97	10** (1.5)	10** (2.2)	10** (1.8)	0
150	215 ± 5	97	10** (1.4)	10** (2.0)	10** (1.9)	1 (2.0)
Female F344/N rats
0	103 ± 4		0	0	0	0
9.5	105 ± 3	102	10** (1.0)	10** (1.0)	8** (1.0)	0
18.75	102 ± 3	100	10** (1.0)	10** (1.4)	10** (1.5)	0
37.5	95 ± 4	97	10** (1.0)	10** (1.4)	9** (1.8)	0
75	97 ± 4	98	10** (1.3)	10** (1.9)	10** (2.0)	0
150	90 ± 3*	95	10** (1.1)	10** (2.1)	10** (1.8)	0
Male B6C3F1/N mice
0	12.3 ± 0.6		0	0	0	0
38	12.7 ± 0.6	103	10** (1.0)	10** (1.0)	10** (1.3)	0
75	11.7 ± 0.6	99	10** (1.0)	10** (1.0)	10** (1.4)	0
150	12.1 ± 0.6	102	10** (1.1)	10** (1.0)	10** (1.5)	0
300	10.3 ± 0.9	96	10** (1.6)	10** (1.2)	10** (1.7)	1 (2.0)
600	10.5 ± 0.6	96	10** (2.2)	10** (1.5)	10** (2.2)	2 (2.0)
Female B6C3F1/N mice
0	11.3 ± 0.6		0	0	0	0
38	12.7 ± 1.1	103	10** (1.0)	10** (1.0)	10** (1.9)	0
75	12.0 ± 0.7	102	10** (1.1)	10** (1.0)	10** (2.1)	0
150	11.3 ± 0.6	98	10** (1.0)	10** (1.0)	10** (2.0)	0
300	9.4 ± 0.7	93	10** (1.4)	10** (1.1)	10** (2.1)	0
600	9.8 ± 0.6	94	10** (1.8)	10** (1.4)	10** (2.1)	3 (2.0)

N = 10. Average severity grades indicated in parenthesis: 1=minimal, 2=mild, 3=moderate, 4=marked.

Significant differences from vehicle control group:

^*p ≤ 0.05 by Williams' test;

^**p ≤ 0.01 by Fisher exact test.